06.03.20
An open letter to the rare disease community updating on Scotland's position with regard to rare disease. The letter sets out detailed progress with regards to its the three priorities of the Rare Disease Strategic Oversight Group (RDSOG); coordination of care,raising awareness of rare disease amongst health professionals and research.
Read more05.03.20
Advice for patients / parents / guardians regarding Coronavirus (COVID-19)...
Read more04.03.20
Oxford, UK / IntraBio Inc. is pleased to announce that the Extension Phase for the IB1001-201 Clinical Trial has been accepted by the FDA (US Food and Drug Administration). The Extension Phase has also been previously approved by all European countries in which the trial is being conducted, including Germany, Slovakia, Spain, and the UK.
Read more02.03.20
Company next plans to meet with European Medicines Agency in second quarter 2020...
Read more20.02.20
Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has completed patient enrollment in its Phase I/II trial to evaluate the safety, tolerability, and efficacy of Trappsol® Cyclo™ administered intravenously to Niemann-Pick Disease Type C1 (NPC1) patients...
Read more
